Laurence Hanssens

Dr. Laurence Hanssens

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in Cells
Verified
Journal Article
Open access
PDF file
LHLaurence Hanssens
Laurence Hanssens
JDJean Duchateau
Jean Duchateau
GCGeorges Jacques Casimir
Georges Jacques Casimir
Cystic fibrosis (CF) is a recessive genetic disease caused by mutations in a gene encoding a protein called Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). The CFTR protein is known to acts as a chloride (Cl−) channel expressed in the exocrine glands of several body systems where it also regulates other ion channels, including the epithelial sodium (Na+) channel (ENaC) that plays a key role in salt absorption. This function is crucial to the osmotic balance of the mucus and its viscosity. However, the pathophysiology of CF is more challenging than a mere dysregulation of epithelial ion transport, mainly resulting in impaired mucociliary clearance (MCC) with consecutive bronchiectasis and in exocrine pancreatic insufficiency. This review shows that the CFTR protein is not just a chloride channel. For a long time, research in CF has focused on abnormal Cl− and Na+ transport. Yet, the CFTR protein also regulates numerous other pathways, such as the transport of HCO3−, glutathione and thiocyanate, immune cells, and the metabolism of lipids. It influences the pH homeostasis of airway surface liquid and thus the MCC as well as innate immunity leading to chronic infection and inflammation, all of which are considered as key pathophysiological characteristics of CF.

1 January 2010 in Journal of Inflammation
Verified
Journal Article
Open access
PDF file
GCGeorges Jacques Casimir
Georges Jacques Casimir
FHFabienne Heldenbergh
Fabienne Heldenbergh
LHLaurence Hanssens
Laurence Hanssens
SMSandra Mulier
Sandra Mulier
CHClaudine Heinrichs
Claudine Heinrichs
JDJean Duchateau
Jean Duchateau
Gender influences clinical presentations and markers in inflammatory diseases. In many chronic conditions, frequency of complications is greater in females, suggesting that continuous inflammatory reaction may induce greater damage in targeted organs and functions.

1 May 2016 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
LHLaurence Hanssens
Laurence Hanssens
ITI. Thiébaut
I. Thiébaut
Nicolas LefèvreNicolas Lefèvre
Nicolas Lefèvre
AMA. Malfroot
A. Malfroot
CKC. Knoop
C. Knoop
GCG. Casimir
G. Casimir

30 March 2021 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
PDF file
LHLaurence Hanssens
Laurence Hanssens
SCSarah Cellauro
Sarah Cellauro
JDJean Duchateau
Jean Duchateau
GCGeorges J. Casimir
Georges J. Casimir
Background and Methods Hypergammaglobulinemia (hyper‐IgG) and hypogammaglobulinemia (hypo‐IgG) have been reported in patients with cystic fibrosis (CF). Although the clinical respiratory course is paradoxically different, depending on the IgG status, this association remains elusive. Therefore, we performed a longitudinal study to assess the annual evolution of IgG profiles in a cohort of pediatric patients with CF, from their diagnosis until 2016. We then compared clinical findings with the patients’ IgG status to determine whether IgG status could reflect the respiratory clinical course of patients with CF. Results Among the 66 patients with CF that were aged between 12 months and 18 years in 2016 (mean age: 9.3 years [SD: 5.2]), hypo‐IgG was observed in 15.2% and no hyper‐IgG was identified. Longitudinal assessment since diagnosis revealed no hyper‐IgG but 33.3% of patients had at least one sample showing hypo‐IgG, among which two patients displayed persistent hypo‐IgG. The number of pulmonary exacerbations, duration of antibiotic therapy, and erythrocyte sedimentation rate were all lower in hypo‐IgG patients. No difference was observed for the genotype, chronic Pseudomonas aeruginosa or Staphylococcus aureus infection, and in the parameters of lung function. Conclusion The IgG profile of pediatric patients with CF has changed over recent decades, particularly with regard to hyper‐IgG. In a significant portion of the pediatric CF population, hypo‐IgG is transient and only identifiable in longitudinal assessments. This study reinforces that hypo‐IgG patients paradoxically present a more favorable course of clinical status. Therefore, IgG levels could be a useful outcome marker in the follow‐up of patients with CF.

1 July 2020 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
LHLaurence Hanssens
Laurence Hanssens
JDJ. Duchateau
J. Duchateau
SNS.A. Namane
S.A. Namane
AMA. Malfroot
A. Malfroot
CKC. Knoop
C. Knoop
GCG. Casimir
G. Casimir

27 April 2023 in Children
Verified
Journal Article
Open access
PDF file
WAWael Alkoussa
Wael Alkoussa
LHLaurence Hanssens
Laurence Hanssens
VSValérie Sputael
Valérie Sputael
FLFrederico De Lucia
Frederico De Lucia
CQChristine Quentin
Christine Quentin
The forced expiratory volume in one second (FEV1) is regularly used for the follow-up of patients with non-cystic fibrosis bronchiectasis (nCF-BE). The lung clearance index (LCI), measured by the multiple breath washout test, has been recently proposed as a lung function measure and a potential tool more sensitive than the FEV1 measured by spirometry in assessing airway changes seen on imaging. While several data have been endorsed as a useful endpoint in clinical trials of patients with early or mild CF lung disease and as the main outcome measure in clinical trials with CFTR modulators in children and adolescents with CF, few data are available in the context of non-CF bronchiectasis. The aim of this pilot study was to compare the LCI with the FEV1 as well as the forced vital capacity (FVC), the forced expiratory flow at 25–75% of the FVC (FEF 25–75%), and chest imaging based on the modified Reiff score in patients with primary ciliary dyskinesia (PCD) and non-CF, non-PCD bronchiectasis (PCD-BE and nCFnPCD-BE). Additionally, we compared each test’s duration and the preferred technique. Twenty children were included; nine had PCD-BE and eleven had nCFnPCD-BE. The median age was twelve years (ages ranging between five and eighteen years). The median LCI was seven while the median z-scores of the FEV1, FVC, and FEF 25–75% were −0.6, 0, and −0.9, respectively. No significant associations or correlations were observed between LCI, spirometric parameters, or the modified Reiff score. However, nearly half of the population (n = 9) had an abnormal LCI, while only 10% had an abnormal FEV1. A total of 75% of children preferred MBW, despite it lasting five times longer than spirometry. In this paper, the authors suggest that LCI might be useful in a cohort of pediatric patients with PCD-BE and nCFnPCD-BE for detecting early lung function changes during their follow-up. Additionally, MBW seems to be preferred by patients. These data may encourage further studies on this topic.